期刊名称：CANCER
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
 Aims and Scope
The CANCER site is a full-text, electronic implementation of CANCER, an Interdisciplinary International Journal of the American Cancer Society, and CANCER CYTOPATHOLOGY, a Journal of the American Cancer Society. The print and online versions of the journal are published by John Wiley & Sons, Inc.
The site offers access to current issues since 1997 of CANCER including CANCER CYTOPATHOLOGY in HTML format, with embedded links to figures and tables, as well as CrossRef TM links, which take users to cited articles that may have been published by a different publisher. There is unrestricted access to tables of contents, abstracts, and general information about CANCER and the CANCER CYTOPATHOLOGY section, as well as to other Wiley journals. The full-text is available to all subscribers following registration .
CANCER publishes interdisciplinary oncologic information according to, but not limited to, the following disease sites and disciplines:
blood/bone marrow
breast disease
endocrine disorders
epidemiology
gastrointestinal tract
genitourinary disease
gynecologic oncology
head and neck disease
hepatobiliary tract
integrated medicine
lung disease
medical oncology
neuro-oncology
pathology
radiation oncology
translational research
The National Board of Directors of the American Cancer Society adopted the following mission statement November 9, 1994: "The American Cancer Society is the nationwide community-based voluntary health organization dedicated to eliminating cancer as a major health problem by preventing cancer, saving lives from cancer, and diminishing suffering from cancer through research, education, and service."
CANCER is a peer-reviewed publication of the American Cancer Society integrating scientific information from worldwide sources for all oncologic specialties. The objective of CANCER is to provide an interdisciplinary forum for the exchange of information among oncologic disciplines concerned with the etiology and course of human cancer. CANCER accomplishes this objective by publishing original articles, as well as other scientific and educational documents, that support the mission of the American Cancer Society by facilitating the transfer of knowledge from the laboratory to the bedside; contributing to cancer prevention, early detection, diagnosis, cure, and rehabilitation; and diminishing suffering from cancer.
CANCER is pleased to receive original articles related to human cancer including, but not limited to: biologic response modifiers (such as growth factors, interferons, interleukins, lymphotoxins), clinical observations, chemotherapy, clinical trials, detection, epidemiology, ethical issues, etiology, genetics and cytogenetics, imaging, immunology and immunotherapy, oncogenes, pathology and clinicopathologic correlations, prevention, psychosocial studies, radiation therapy, screening, staging, and surgical therapy.
In addition to Original Articles, CANCER publishes other categories including solicited Editorials, Commentaries, Review Articles, and Correspondence. The final decision on publication of a manuscript rests with the Editorial Board and ultimately with the Editor-in-Chief. All papers, regardless of type, represent the opinion of the authors and not necessarily that of the American Cancer Society, the Editors, or the Publisher.
Instructions to Authors
INSTRUCTIONS FOR AUTHORS
The most up-to-date version of the instructions is located at
the CANCER Web site at http://www.interscience.wiley.com/cancer.
Mission and Scope of the American Cancer Society and
CANCER: The National Board of Directors of the American Cancer
Society adopted the following mission statement November
9, 1994: ‘‘The American Cancer Society is the nationwide community-
based voluntary health organization dedicated to eliminating
cancer as a major health problem by preventing cancer,
saving lives and diminishing suffering from cancer through research,
education, advocacy, and service.’’ CANCER is a peerreviewed
publication of the American Cancer Society integrating
scientific information from worldwide sources for all oncologic
specialties. The objective of CANCER is to provide an interdisciplinary
forum for the exchange of clinically applicable information
among oncologic disciplines concerned with the etiology
and course of human cancer. CANCER accomplishes this objective
by publishing original articles, as well as other scientific and
educational documents, that support the mission of the American
Cancer Society by facilitating the transfer of knowledge from
the laboratory to the bedside; contributing to cancer prevention,
early detection, diagnosis, cure, and rehabilitation; and diminishing
suffering from cancer.
MANUSCRIPT TYPES AND LENGTH LIMITATIONS
Length Limitations
Papers that grossly exceed the length limitations as described
in this guide will not be considered for review.
Original Articles: Scientific reports of the results of original
clinical research. The text is limited to 6000 words including
the title page, abstract, text, references, figures, figure legends,
and tables. Abstracts are limited to 250 words.
Accelerated Publications: A concise and timely presentation
of significant data. The text should not exceed 2400 words
with no more than 20 references and a total of four figures
and tables. Expedited peer review and publication is rare
and subject to approval by the Editor-in-Chief.
Review Articles: A timely, in-depth treatment of an issue.
Review articles are generally solicited by the editors, but unsolicited
materials will be considered. Review articles must be
no longer than 8000 words including title page, abstract, text,
tables, figures, figure legends, and references.
Editorials: Opinions of recognized leaders in oncologic specialties.
Editorials are generally solicited by the Editor-in-Chief and
are related to a manuscript in the same issue. Length should not
exceed 2400 words with no more than 20 references.
Commentaries: Presents a point of view of general interest
not related to an article in the same issue of CANCER.
Communications: Brief notes on selected topics from organizations
such as the American Cancer Society, the Commission
on Cancer of the American College of Surgeons, and the
American Joint Committee on Cancer.
In Memoriam: Highlights the accomplishments of distinguished
individuals who are deceased for their contributions
to oncology.
Correspondence: Commentaries related to papers previously
published in CANCER. Letters must be submitted within three
months of the online publication date of the article discussed
in order to be considered. The authors of the original publication
will be given the opportunity to respond in the same issue
of CANCER. Letters and responses must not exceed 400 words
in length, must be limited to three authors and five references,
and should not have tables or figures. Financial associations or
other potential conflicts of interest must be disclosed.
Case reports of single cases will not be considered.
MANUSCRIPT SUBMISSION REQUIREMENTS
Electronic submission
All manuscripts must be submitted electronically using CANCER’s
Manuscript Central Web site available at http://mc.manuscriptcentral.
com/cancer. Manuscripts may not be submitted by
Revised 5/08
Please note: All correspondence for the journal should be
sent to the following address. Please include the manuscriptnumber
with all correspondence (example: CNCR-09-0000):
CANCER Editorial Office
American Cancer Society
250 Williams Street
Atlanta, GA 30303-1002
Phone: (404) 327-6411
FAX: (404) 551-5650
E-mail: canceredoff@cancer.org
E-mail. Submit text files only as .DOC or .RTF file formats.
DOCX and other file formats are not permitted and should be
converted to DOC. In addition to submitting online, authors are
required to mail, e-mail, or FAX the following to the CANCER
Editorial Office: the ‘‘Authorship Responsibility, Financial Disclosure,
and Copyright Transfer’’ form signed by all authors; any
permissions that may have been obtained for figures or tables;
any permissions required for patient consent. Please include
the permanent manuscript number on all correspondence.
The following items are required to be included with the
online submission:
Cover letter that includes the statement ‘‘All authors have
read and approved the manuscript’’ as well as any additional
information that may impact the review process
Manuscript category (e.g., Editorial, Review Article, Original
Article, etc.)
The anatomic site or general topic best suited for the original
article
Reviewer suggestions that include names, addresses, phone/
AX numbers, and E-mail addresses
Corresponding author’s complete contact information to
include address, phone/FAX numbers, and E-mail address.
Any changes to this information must be sent immediately
to the CANCER Editorial Office and be updated at http://
mc.manuscriptcentral.com/cancer
Informed consent: A statement is required with any report
of investigations involving human subjects confirming that
informed consent was obtained from the subject(s) and/or
guardian(s). Provide this statement in the cover letter and state
clearly in the manuscript that informed consent was obtained.
Clinical Trial Registry: CANCER now requires that all prospective,
randomized, controlled trials with patient enrollment
starting on or after August 1, 2007, be registered in a public
database that meets the requirements of the World Health
Organization. Currently, such registries include the following:
www.actr.org.au, www.clinicaltrials.gov, www.ISRCTN.org, www.
umin.ac.jp/ctr/index/htm, and www.trialregister.nl. For more
information, please refer to the guidelines at http://www.
icmje.org/#clin_trials. Upon submission, please provide the
registration identification number and the URL for the trial’s
registry in your cover letter.
MANUSCRIPT COMPONENTS
General Style
Prepare the manuscript using American spelling and grammar.
Use the following sources as guidelines for manuscript preparation
and style:
Matters of spelling, capitalization, punctuation, hyphenation,
reference format, and general style: American Medical Association
Manual of Style, 9th ed.1
Citing cancer stages: American Joint Committee on Cancer
Staging Manual, 6th ed.2 or UICC TNM Classification of
Malignant Tumours3
Histologic classification of tumors: World Health Organization
International Histological Classification of Tumours4
Drug naming: USP Dictionary of USAN and International
Drug Names, 19975
Chemical terms: Naming and Indexing of Chemical Substances
for Chemical Abstracts6
Terms relating to diseases, operations, and procedures:
ICD-O: International Classification of Diseases for Oncology,
2nd ed.,7 Physicians?Current Procedural Terminology: CPT,
1995,8 and SNOMED International9
Presenting statistical material: Cancer Treatment Reports10
Abbreviating journal titles in references: Index Medicus11
Units ofmeasure: Syste´me International (SI) ormetric system.
Manuscript Format
The following components are required for a complete manuscript:
cover letter, title page, abstract, text, references, figure
legends, publication quality figures, and tables. Include page
numbers on the document, beginning with the title page as
number 1. Please use standard 10- or 12-point font size.
Title page
The following items are required on the title page:
Manuscript title
Running title: a short version of the title (up to 40 characters
including spaces)
Each author’s name, academic degrees, and affiliation (limited
to 10 authors)
Complete mailing address, telephone, facsimile, and E-mail
for correspondence and reprints
Total number of each: 1) text pages, including title page,
references, and figure legends; 2) tables; and 3) illustrations
Sources of support that require acknowledgment including
NIH grant numbers.
All financial disclosures. If there are no financial disclosures
from any authors. Please state that as well
Condensed abstract for use in the Table of Contents: two
concise sentences that state the significant conclusion(s) or
message of the manuscript (not required for In Memoriam
or Correspondence) Abstract: Original and Review Articles must contain an abstract
of approximately 250 words. Structured abstracts are required
for Original Articles and must have four specified subtitles:
Background,Methods, Results, and Conclusion(s). Abstracts are
not required for InMemoriam, Editorials, Commentaries, Communications,
or Correspondence. Abstracts published in CANCER
are submitted to the International Cancer Research Data
Bank (ICRDB), supported by the National Cancer Institute. This
facilitates broad circulation of cancer-related abstracts. If the
ICRDB edits an abstract significantly, it is indicated by a notation
‘‘modified.’’ Authors are hereby made aware of this procedure
in advance of submitting a manuscript to CANCER.
Keywords: 4 to 10 key words or terms to be used as index
terms. Use terms from the medical subject headings list of
Index Medicus.11
Drugs
Use generic name (or generic name followed by trade name in
parentheses), manufacturer and their location (city and country).
Abbreviations
Use only standard abbreviations and spell out all abbreviations at
first use in the text followed by the abbreviation in parentheses.1
Appendices
Supplemental materials presented as appendices are not permitted.
These materials must either be placed within the
manuscript or eliminated.
A2
Classification and staging
AJCC/UICC TNM Classification and Stage groupings are to be
used. If another staging system is stated, the AJCC/UICC TNM
equivalent must also be given.2,3 The stage grouping is a combination
of the individual T, N, M classifications (e.g., Breast Carcinoma
Stage IIA is T2 N0 M0. Please note IIA is the stage. T2 N0M0
is a combination of T, N, M classifications that satisfy the criteria
for Stage IIA.). Reference to any T, N,Mcomponent is a classification
and not a stage (e.g., the T2 classification); it is not correct to
state the classification as a stage (e.g., the T2 stage). When a stage
or classification is used in the manuscript, a reference citing the
staging system must be provided. The first time a stage is used it
must be accompanied by the T, N,Mand the verbal translation of
the numerical identifier (e.g., Breast Carcinoma Stage IIA [T2 N0
M0]): tumor more than 2 cm but not more than 5 cm in greatest
dimension [T2], no regional lymph node metastasis [N0], no distant
metastasis [M0]).
Statistical analysis
The following guidelines should be followed including statistical
analyses:
Report the sample size n for each study and each analysis
Describe the power analysis to justify the sample size if
appropriate
Identify all statistical methods and verify the assumptions
for all statistical tests
Provide alpha (the probability of a Type I error) for all statistical
tests
Specify whether tests are one- or two-sided
Report the descriptive statistics (n, mean, median, and standard
deviation) for all continuous variables
Report n and the sample proportion for binary variables
Adequately explain complex statistical procedures such asmultivariate
logistic regression and theCox proportional hazard regression
model and verify the assumptions of each such procedure
Report the actual P-values and explain what is meant by statistical
significance
Discuss and describe adjustments for multiple testing
References
If using EndNote (recommended), the CANCER reference style can
be downloaded at www.interscience.wiley.com/jendnotes/. For
assistance using EndNote, contact endnote@isiresearchsoft.com
or visitwww.endnote.com/support.
Format. Submit references per the following instructions:
List references double-spaced in a separate reference section
immediately following the text.
Verify all references prior to submission.
Use the American Medical Association Manual of Style, 9th ed.1
for reference format style and Index Medicus11 for standard
journal abbreviations (examples to follow).
Number references sequentially in the order cited in the text;
do not alphabetize. Remove automatic numbering and linked
citations; number references manually.
Do not cite personal communication, unpublished observations,
and submitted manuscripts. Reference to a paper
accepted but not yet published can be listed as ‘‘in press.’’
‘‘In press’’ references must be updated by the authors as
soon as publication data are available.
Provide names of all authors in a reference when there are
six or fewer; if there are seven or more authors, list only the
first three, followed by ‘‘et al.’’
Reference types. Following are requirements and examples for
common reference types:
Journal references include the specified information listed
in the following order—authors, article title and subtitle,
journal abbreviation, year, volume number in Arabic numerals,
and inclusive pages.
Example: 1. Cohn KH, Ornstein DL, Wang F, et al. The significance
of allelic deletions and aneuploidy in colorectal carcinoma:
results of a 5-year follow-up study. Cancer. 1997;79: 233?44.
Book references include the following: authors, title, edition (if
other than the first), volume (if more than one), city, publisher,
and year. When referencing a book chapter, the order
changes as follows: authors of the chapter, title of the chapter,
‘‘In:’’, editors/authors of the book, title of the book, edition
(if there aremore than one), volume (if there aremore than one),
city, publisher, year, and inclusive pages of the chapter.
Example: 2. Givan AL. Flow Cytometry: First Principles. 2nd ed.
New York: John Wiley & Sons, Inc., 2001.
Example: 3. Luketich JD, Ginsberg RJ. Diagnosis and staging
of lung cancer. In: Johnson BE, Johnson DH, editors. Lung
Cancer. New York: Wiley-Liss, Inc., 1995:161?73.
Electronic sources should include the type of medium (such
as ‘‘computer program’’ or ‘‘CD-ROM’’), the version used, and
the supplier. References to online sources should include the
type of medium(such as ‘‘serial online’’ or ‘‘monograph online’’),
the date of that specific reference (if applicable), the uniform
resource locator (URL), and the date that the source was
accessed. For web pages, please include the name of the page
referenced. A source accessed online should always be referenced
accordingly, even if it is also published in printed form.
Example: 4. Nakamura S, Yao T, Aoyagi K, Ikda M, Fujishima M,
Tsuneyoshi M. Helicobacter pylori and primary gastric lymphoma:
a histopathologic and immunochemical analysis of 237
patients. Cancer [serial online] 1997;79:3?1. Available from URL:
http://www.interscience.wiley.com/cancer [accessed Dec 1, 1998].
Example: 5. American Cancer Society. Cancer reference information.
Available from URL: http://www.cancer.org/docr007/
CRI/CRI_0.asp [accessed January 26, 2006].
Authors are responsible for the accuracy and completeness
of their references and for correct text citation.
Tables
Submit single-spaced on separate pages in the word processing
program used. Tables imported into the word-processing
program from spreadsheet programs (e.g., Microsoft
Excel) should be left in table format and not converted to
text. Gridlines should be retained.
Do not embed tables as graphic files. They cannot be edited
by the publisher.
Limit tables to those that adequately and concisely present
findings without redundancy.
Cite all tables in the text. Number tables consecutively, using
Arabic numerals, in the order cited in the text. The table
number is followed by a brief descriptive title.
Include table number, ‘‘continued,’’ and table subheadings
on each page if a table exceeds one manuscript page.
A3
Define all abbreviations used in the table in footnotes to the table.
Obtain written permission to reproduce previously published
tabular material. Credits for the reproduced work are included
as a footnote to the table andmust include author(s), title, either
publisher and city (and country, if other than US) or periodical
name, volume, page, and year. Signed permission forms must
be sent to the CANCER Editorial Office upon submissions.
Figures and legends
Submit only publication quality figures in TIFF or EPS file format.
Call out all figures in the text. Number all figures sequentially
with Arabic numerals in the order cited in the text.
Provide double-spaced legends on a separate page to include
the figure number and a brief description of the figure.
Figures with multiple parts should be labeled and referred to
as (a), (b), (c), etc.
Obtain written permission to reproduce previously published
figures. Credits for the reproduced work are included in the
figure legend and must include author(s), title, either publisher
and city (and country, if other than US) or periodical name,
volume, page, and year. Signed permission forms must be sent
to the CANCER Editorial Office upon submissions.
Submit photographs and line art only as TIFF or EPS file formats.
JPEG or GIF files are not permitted.
Do not embed figures in word processing programs (e.g.,
Microsoft Word).
Mask any patient identification in photographs; otherwise, a
signed permission statement is required (please see Permissions
section).
Note: Color figures are published in print and online free of
charge at the discretion of the editor.
AUTHORS?PROFESSIONAL AND ETHICAL
RESPONSIBILITIES
Should possible scientific misconduct or dishonesty in research
submitted for review be suspected or alleged, CANCER reserves
the right to forward any submitted manuscript to the sponsoring
or funding institution or to other appropriate authorities for investigation.
CANCER recognizes the responsibility to ensure that the
question is appropriately pursued, but does not undertake the
actual investigation or make determinations of misconduct. The
author will be notified if CANCER forwards any manuscript or
materials to the sponsoring or funding institution.
Authorship
Authorship responsibility, financial disclosure, and
copyright transfer
Each author should have participated sufficiently in the work to
take public responsibility for the content. Authorship credit should
be based only on substantial contributions to 1) Conception and
design, or analysis and interpretation of data; 2) Drafting the article
or revising it critically for important intellectual content; and 3)
Final approval of the version to be published. All three conditions
must be met.12 Carefully review author status prior to submitting a
manuscript. Changes to the author list (deletions and additions)
may not be permitted once a manuscript is in review. Each author
must read and sign the statements on:
1. Authorship responsibility, criteria, and contributions
2. Financial disclosure
3. Either copyright transfer or US Government employment.
The corresponding author is responsible for collecting the signatures
of all authors. The signed forms must be sent to the
CANCER Editorial Office upon manuscript submission.
The number of authors on a manuscript should not
exceed 10. Manuscripts exceeding this limit will be returned
without review. However, group authorship may be used in
any of the following three formats as appropriate:
1. Authorship may be attributed to an entire group (e.g.,
Pediatric Oncology Group) when all members of the group meet
the criteria for authorship previously outlined. In this case, the
name of the group is located on the title page in the place of
authors; each member of the group is listed in a footnote and
his/her authorship acknowledged. Each member of the group
must sign the ‘‘Authorship Responsibility, Financial Disclosure,
and Copyright Transfer’’ form.
2. The names of up to 10 authors may be listed on the
title page, followed by the name of the group (e.g., Jane E. Doe,
John L. Smith, Mark F. Jones, and the Pediatric Oncology
Group) when the individual authors, as well as all members of
the group, meet the criteria for authorship previously outlined.
In this case, group members are listed in a footnote and their
authorship acknowledged. Each member of the group must
sign the ‘‘Authorship Responsibility, Financial Disclosure, and
Copyright Transfer’’ form.
3. When specified authors assume responsibility for an
entire group (e.g., Jane E. Doe, John L. Smith, Mark F. Jones for
the Pediatric Oncology Group), only the specified authors must
meet the criteria for authorship previously outlined. All members
of the group may be listed in a footnote but are not acknowledged
as authors. In this case, the corresponding author must
state in the cover letter that she/he has written permission from
each group member to list her/his name as a member of the
group.
CANCER’s ‘‘Authorship Responsibility, Financial Disclosure,
and Copyright Transfer’’ form is available online at http://
www.interscience.wiley.com/cancer. Signatures of every author
are required. Please include the manuscript number on the form.
National Institutes of Health Grantees
Wiley-Blackwell will post the accepted version of articles by
NIH grant-holders to PubMed Central upon acceptance by
the journal on the authors?behalf. The accepted version is
the version that incorporates all amendments made during
peer review, but prior to the publisher’s copy-editing and typesetting.
This accepted version will be made publicly available
12 months after publication. The NIH mandate applies to all articles
based on research that has been wholly or partially funded
by the NIH and that are accepted for publication on or after April
7, 2008.
Simultaneous submission and online posting
CANCER will not consider papers that are simultaneously submitted
elsewhere or have been published (to include online). If a
manuscript is posted to an author’s Web site (or their institution’s
site), it must be taken down prior to submission. Manuscripts
cannot be posted online until after the paper has been published
in CANCER and only if permission has been granted by the publisher
and the article properly cited. Clinical trial results may
not be published online prior to journal publication.
A4
Permissions
Use of previously published or copyrighted material
Information reproduced from another source must be properly
cited. The corresponding author is responsible for obtaining
written permission from the appropriate authors and/or copyright
holders to use previously published or copyrighted material.
Signed permission statements from the copyright holder for
both print and online reproduction must be sent to the CANCER
Editorial Office upon manuscript submission. Permission statements
also must be obtained from at least one author when citing
unpublished data, in press articles, and/or personal
communications. Permission forms may be obtained by contacting
the CANCER Editorial Office or online at www.interscience.
wiley.com/cancer.
Photographs with identifiable patients
In photographs, sonograms, CT scans, etc., the physical identification
of a patient should be masked whenever possible. If a patient
is identifiable, written permission to use the photograph must be
obtained from the patient or guardian and sent to the CANCER
Editorial Office upon manuscript submission. Clearly state in the
manuscript that informed consent has been obtained.
Randomized Controlled Trials
Reports of Randomized Controlled Trials (RCTs) must state
explicitly how the comparison groups were generated, so that
readers will be able to assess the method of randomization. In
the title, pre´cis, and abstract, specify that the manuscript is a
report of an RCT. Prior to submitting an RCT manuscript,
authors should refer to the CONSORT checklist.13
Reports of Diagnostic Tests
Authors of reports of diagnostic tests are encouraged to submit
the STARD flow diagram and checklist.14
Embargo Policy
Once submitted, contributions cannot be discussed with the
media until one week before the publication date. Accepted articles
are embargoed from reporting by all media until 12:01 A.M.
(EST) on the date of issue. Authors who discuss their work with
the media prior to publication must ensure that the media representatives
know the embargo policy and the embargo date.
Authors arranging their own publicity on their articles are
advised to notify the CANCER Editorial Office in advance.
PRODUCTION
Proofs to Authors
Page proofs for accepted manuscripts are sent via e-mail to the
corresponding author from the Publisher, John Wiley & Sons,
Inc. The corresponding author must return all proof corrections
within 48 hours and limit changes to corrections of typographical
errors and errors in the presentation of data. Correspondence
regarding proofs should be directed to CANCER
Production Editor, John Wiley & Sons, Inc., 111 River St., Hoboken,
NJ 07030-5774, USA. Telephone: (201) 748-5847; Facsimile: (201)
748-6825; E-mail: cncrprod@wiley.com
Reprints
A form for ordering reprints is forwarded to the corresponding
author with the page proofs. To request additional forms, contact
the Reprints Department, John Wiley & Sons, Inc., 111 River
St., Hoboken, NJ 07030-5774, USA. Telephone: (201) 748-8771;
Facsimile: (201) 748-6021; E-mail: cwoods@wiley.com.
Copying
2009 American Cancer Society. All rights reserved. No part of
this publication may be reproduced in any form or by any means,
except as permitted under section 107 or 108 of the 1976 United
States Copyright Act, without either the prior written permission of
the publisher, or authorization through the Copyright Clearance
Center (CCC) Transactional Reporting Service, provided that the
base fee of $10.00 per copy is paid directly to CCC, 222 Rosewood
Drive, Danvers, MA 01923 USA, ISSN 0008-543X/09/$10.00. For
authorization for other kinds of copying, contact Permissions
Department, John Wiley & Sons, Inc., 111 River St., Hoboken, NJ
07030-5774, USA. Telephone: (201) 748-6011; Facsimile: (201) 748-
6008; E-mail: permreq@wiley. com.
Communications to the Publisher
For business inquiries, subscription information, orders, or subscriber
changes of address, contact John Wiley & Sons, Inc., 111
River St., Hoboken, NJ 07030-5774, USA; or call (201) 748-6995
(toll-free 1-800-511-3989); Facsimile: (201) 748-6021; E-mail:
subinfo@wiley.com.
REFERENCES
1. American Medical Association Manual of Style: A Guide for
Authors and Editors. 9th ed. Baltimore: Lippincott Williams
& Wilkins, 1998.
2. Greene FL, Page DL, Fleming ID, et al, eds. American Joint
Committee on Cancer Staging Manual. 6th ed. Philadelphia:
Springer, 2002.
3. Sobin LH, Wittekind Ch., eds. TNM Classification of malignant
tumors. 5th ed. NewYork: JohnWiley&Sons, Inc., 1997.
4. World Health Organization. International histological classification
of tumours. 2nd ed. Geneva: World Health Organization,
1969?981; Berlin: Springer-Verlag, 1988–Present.
5. USP Dictionary of USAN and International Drug Names,
1998. Rockville, MD: U.S. Pharmacopeia, 1997.
6. Chemical Abstracts Services. Naming and indexing of chemical
substances for chemical abstracts, Appendix IV.
Columbus, OH: Chemical Abstracts Services, 1997.
7. ICD-O: International classification of diseases for oncology.
2nd ed. Geneva: World Health Organization, 1990.
8. Physicians?current procedural terminology: CPT, 1998. Chicago:
JA Majors Co., 1998.
9. Cote RA, Rothwell DJ, Beckett RS, Palotay JL, eds. SNOMED
international: the systematized nomenclature of human and
veterinary medicine. 4 vols. Northfield, IL: College of American
Pathologists, 1993.
10. National Cancer Institute. Cancer treatment reports.
Washington, DC: National Cancer Institute, 1985;69:1?.
11. National Library of Medicine. List of journals indexed in
index medicus. Washington, DC: US Government Printing
Office [published annually].
12. International Committee of Medical Journal Editors. Uniform
requirements for manuscripts submitted to biomedical journals.
Ann Intern Med. 1997;126:36?7. Available from: URL:
http://www.icmje.org [accessed 18 November 2003].
13. Moher D, Schultz KF, Altman D, for the CONSORT Group.
The CONSORT statement: revised recommendations for
improving the quality of reports of parallel-group randomized
trials. JAMA. 2001;285:1987?991.
14. Bossuyt PM, Reitsma JB, Bruns DF, et al. for the STARD
Group. Towards complete and accurate reporting of studies
of diagnostic accuracy: the STARD initiative. Clin Chem. 2003;
49:1?8. Available from URL: http://www.clinchem.org/
cgi/content/full/49/1/1/ [accessed Sep 13, 2005].
A5
CANCER
Checklist for Authors
Please use this checklist to ensure that all required
pieces accompany your submission. Failure
to provide these items may result in a delay of
review.
u Length limitations: Manuscripts exceeding the
following length limitations will be returned without
review–Original Articles (6000 words); Review
Articles (8000 words). All elements including title
page, abstract, text, figures, figure legends, tables,
and references are included in the word count.
Title Page:
u Corresponding author with all contact information
u Names, affiliations, and academic or professional
degrees of each (no more than 10 permitted)
author
u Shortened title of no more than 40 characters,
including spaces
u Manuscript category: Original Article (specify an
anatomic site or a general topic), Editorial, Commentary,
Review Article, etc.
u Any acknowledgements
u All financial disclosures, funding considerations
(including NIH funding), and conflicts of interest
u A statement confirming patients?informed consent,
if applicable
u A page count along with a count of tables and
figures
u Condensed Abstract: two concise sentences
summarizing all significant findings
u Abstract: No more than 250 words. Original
Articles must contain Background, Methods, Results,
and Conclusions
& Keywords: between 4 and 10 keywords must
follow the abstract.
Text and formatting:
u Double-spaced throughout, ragged right margin,
and size 10- or 12-point font
u References: properly formatted and numbered
Figures:
u Must appear on separate pages at the end of the
manuscript
u Must be sequentially numbered and called-out
in the text
u Legends should appear on a page separate from
the figures themselves
u Should not be embedded in word processing
documents but rather submitted in TIFF or EPS file
formats
u Any figures being reproduced from another
source must have permission and proper credit. All
signed permissions must be sent to the CANCER Editorial
Office.
Tables:
u Submitted single-spaced and in the word processing
software used. Do not embed tables as graphic
files, document objects, or pictures.
u Any tables being reproduced from another
source must have permission and proper credit. All
signed permissions must be sent to the CANCER Editorial
Office.
To submit a manuscript:
1. Submit manuscript electronically at http://mc.
manuscriptcentral.com/cancer.
2. Send the following items bymail or facsimile [include
the manuscript number on all correspondence (example:
CNCR-09-0000)] to the CANCER Editorial Office:
u ‘‘Authorship Responsibility, Financial Disclosure,
and Copyright Transfer’’ form signed by ALL of the
authors (original signatures required)
u Signed copies of any permissions that may have
been acquired (figures, tables, patient consent)
Instructions to Authors
0008-543X.pdf
Editorial Board
Editorial Board
--------------------------------------------------------------------------------
Editorial Board for CANCER
Editorial Board for the CANCER CYTOPATHOLOGY
--------------------------------------------------------------------------------
Editor-in-Chief
Raphael E. Pollock, MD, PhD
UT M. D. Anderson Cancer Center
Houston, Texas
( canceredoff@cancer.org )
Editorial Staff
Esmeralda Galán Buchanan, Journals Director
Angela Cochran, Managing Editor
Nicki Salcedo, Assistant Managing Editor
Anita Bell Neal, Editorial Assistant
Jessica Hoback, Editorial Assistant
Jin Kim, Editorial Assistant
Daniel Nadolny, Production Assistant
Susie Weetman, Editorial Coordinator
Section Editor for Europe
David Khayat, MD, PhD
Salpetriere Hospital
Paris, France
Section Editors/Discipline
Janet Abrahm, MD
Dana-Farber Cancer Institute
Boston, Massachusetts
Palliative Care and Psychosocial Oncology
Alex Adjei, MD, PhD
Roswell Park Cancer Institute
Buffalo, New York
Medical Oncology
Robert Bast, MD
UT M. D. Anderson Cancer Center
Houston, Texas
Translational Research
Smita Bhatia, MD
City of Hope Comprehensive Cancer Center
Duarte, California
Outcomes Research
Melissa Bondy, PhD
UT M. D. Anderson Cancer Center
Houston, Texas
Epidemiology
Carolyn Compton, MD
National Institutes of Health
Bethesda, Maryland
Pathology
James Cusack, Jr., MD
Massachusetts General Hospital
Boston, Massachusetts
Bench-to-Bedside Reviews
Donna Greenberg, MD
Massachusetts General Hospital
Boston, Massachusetts
Palliative Care and Psychosocial Oncology
Melissa Hudson, MD
St. Jude Children's Research Hospital
Memphis, Tennessee
Pediatric Oncology
Lisa Newman, MD
University of Michigan Cancer Center
Ann Arbor, Michigan
Disparities Research
Edward F. Patz, Jr., MD
Duke University Medical Center
Durham, North Carolina
Diagnostic Imaging
Alan Pollack, MD, PhD
Sylvester Cancer Center
Miami, Florida
Radiation Oncology
Section Editors/Disease Site
Robert Bresalier, MD
UT M. D. Anderson Cancer Center
Houston, Texas
Gastrointestinal Tract
Henry Friedman, MD
Duke Medical Center
Durham, North Carolina
Neuro-oncology
Fadlo Khuri, MD
Emory University School of Medicine
Atlanta, Georgia
Lung Disease
Elise Kohn, MD
National Institutes of Health
Bethesda, Maryland
Gynecologic Oncology
Badrinath Konety, MD
University of California, San Francisco
San Francisco, California
Genitourinary Disease
Lori Lowe, MD
University of Michigan
Ann Arbor, Michigan
Skin
Kim A. Margolin, MD
University of Washington School of Medicine
Seattle, Washington
Melanoma
Jeffrey A. Norton, MD
Stanford University Medical
Center
Stanford, California
Endocrine Disorders
Susan O'Brien, MD
UT M. D. Anderson Cancer Center
Houston, Texas
Hematologic Malignancies
Raphael E. Pollock, MD, PhD
UT M. D. Anderson Cancer Center
Houston, Texas
Soft Tissue
Brian I. Rini, MD
Cleveland Clinic
Cleveland, Ohio
Genitourinary Disease
S. Eva Singletary, MD
UT M. D. Anderson Cancer Center
Houston, Texas
Breast Disease
Kenneth K. Tanabe, MD
Massachusetts General Hospital
Boston, Massachusetts
Hepatobiliary Tract
Randal Weber, MD
UT M. D. Anderson Cancer Center
Houston, Texas
Head and Neck Disease
Editor Emeritus
Robert V.P. Hutter, MD
--------------------------------------------------------------------------------
David Adelstein, MD
Jaffer A. Ajani, MD
Elias J. Anaissie, MD
Andrea M. Barsevick, DNSc
Marianne Berwick, PhD
Rachel F. Brem, MD
Abenaa Brewster, MD, MHS
Harry B. Burke, MD, PhD
Aman U. Buzdar, MD
Paul B. Chapman, MD
Ravi S. Chari, MD
Allan I. Covens, MD
Christopher H. Crane, MD
Anthony V. D’Amico, MD
Gary E. Deng, MD
Neil M. Ellison, MD
David M. Euhus, MD
Keith T. Flaherty, MD
Debra Friedman, MD
Mark R. Gilbert, MD
Sharon H. Giordano, MD, MPH
Lyon L. Gleich, MD
Mary K. Gospodarowicz, MD
Cesare Gridelli, MD
Michael T. Halpern, MD, PhD
Donald Earl Henson, MD
Ronald B. Herberman, MD
Samuel B. Ho, MD
Jean Hurteau, MD
Robert T. Jensen, MD
Armand Keating, MD
Lisa B. Kenney, MD, MPH
Eric A. Klein, MD
Robert G. Maki, MD, PhD
Maurie Markman, MD
William M. Mendenhall, MD
William H. Meyer, MD
Monica Morrow, MD
Jeffrey Myers, MD
Larry Nathanson, MD
Electra D. Paskett, PhD
Carlos A. Perez, MD
Charles A. Powell, MD
David A. Reardon, MD
Peter G. Rose, MD
Jatin P. Shah, MD
Anil K. Sood, MD
Charles Staley, MD
Herman D. Suit, MD
Ayalew Tefferi, MD
Martin Tobi, MD, ChB
Dean Troyer, MD
--------------------------------------------------------------------------------
CANCER ?International Interdisciplinary Journal of the American Cancer Society
Editor-in-Chief
Raphael E. Pollock, MD, PhD
Editorial Staff
Esmeralda Galán Buchanan, Journals Director
Angela Cochran, Managing Editor
Nicki Salcedo, Assistant Managing Editor
Anita Bell Neal, Editorial Assistant
Jessica Hoback, Editorial Assistant
Jin Kim, Editorial Assistant
Daniel Nadolny, Production Assistant
Susie Weetman, Editorial Coordinator
CANCER CYTOPATHOLOGY ?A Journal of the American Cancer Society
Principal Editor
Celeste N. Powers, MD, PhD
Associate Editors
Michael B. Cohen, MD
Terence J. Colgan, MD
Ritu Nayar, MD
Editorial
Advisory Board
Syed Z. Ali, MD
Raheela Ashfaq, MD
Manon Auger, MD
Zubair W. Baloch, MD, PhD
Ricardo H. Bardales
Barbara D. Benstein, PhD
Christine Bergeron, MD, PhD
George Birdsong, MD
Leonard Bloom, MPH
Julia A. Bridge, MD
Ricardo Cajulis, MD
David Chhieng, MD, MBA, MSHI
Edmund S. Cibas, MD
Douglas P. Clark, MD
Diane D. Davey, MD
Catherine I. Dumur, PhD
Hormoz Ehya, MD
Tarik M. Elsheikh, MD
Isam A. Eltoum, MD, MBA
William C. Faquin, MD, PhD
Patricia A. Fetsch, MT (ASCP)
Armando C. Filie, MD
Anton Hopman, PhD
David B. Kaminsky, MD, FIAC
Kusum Kapila, MBBS, MD, FRCPath
Ruth L. Katz, MD
Tado K. Kobayashi, PhD
Gladwyn Leiman, MBBCh, FIAC, FRCPath
Britt-Marie E. Ljung, MD
Sue Ellen Martin, MD, PhD
Chris J.L.M. Meijer, MD, PhD
Dina R. Mody, MD
Ann T. Moriarty, MD
Robert Y. Osamura, MD
Christopher N. Otis, MD
Ibrahim Ramzy, MD
Andrew Renshaw, MD
David L. Rimm, MD, PhD
Dorothy L. Rosenthal, MD, FIAC
Beatriz A. Salvagno, MD
Miguel A. Sanchez, MD
Torill Sauer, MD
Suzanne Selvaggi, MD
Mark E. Sherman, MD
Mary K. Sidawy, MD
Nour Sneige, MD
Mark H. Stoler, MD
Lászl?Vass, MD, PhD, FIAC
Philippe Viehl, MD, PhD
G. Peter Vooijs, MD, PhD, FIAC
Paul E. Wakely, Jr., MD
Helene G. Wiener, MD, PhD
David C. Wilbur, MD
Eva M. Wojcik, MD
Bin Yang, MD, PhD
Grace C. H. Yang, MD
Nancy A. Young, MD, FCAP
Maureen F. Zabowski, MD
|
